IL127384A0 - Method of treating malignant tumors with thyroxine analogues having no significant hormonal activity - Google Patents

Method of treating malignant tumors with thyroxine analogues having no significant hormonal activity

Info

Publication number
IL127384A0
IL127384A0 IL12738497A IL12738497A IL127384A0 IL 127384 A0 IL127384 A0 IL 127384A0 IL 12738497 A IL12738497 A IL 12738497A IL 12738497 A IL12738497 A IL 12738497A IL 127384 A0 IL127384 A0 IL 127384A0
Authority
IL
Israel
Prior art keywords
malignant tumors
thyroxine
hormonal activity
thyroxine analogues
treating malignant
Prior art date
Application number
IL12738497A
Other languages
English (en)
Original Assignee
Octamber Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/655,267 external-priority patent/US5736576A/en
Application filed by Octamber Inc filed Critical Octamber Inc
Publication of IL127384A0 publication Critical patent/IL127384A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/76—Esters of carboxylic acids having a carboxyl group bound to a carbon atom of a six-membered aromatic ring
    • C07C69/84—Esters of carboxylic acids having a carboxyl group bound to a carbon atom of a six-membered aromatic ring of monocyclic hydroxy carboxylic acids, the hydroxy groups and the carboxyl groups of which are bound to carbon atoms of a six-membered aromatic ring
    • C07C69/92—Esters of carboxylic acids having a carboxyl group bound to a carbon atom of a six-membered aromatic ring of monocyclic hydroxy carboxylic acids, the hydroxy groups and the carboxyl groups of which are bound to carbon atoms of a six-membered aromatic ring with etherified hydroxyl groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IL12738497A 1996-06-04 1997-05-30 Method of treating malignant tumors with thyroxine analogues having no significant hormonal activity IL127384A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/655,267 US5736576A (en) 1996-06-04 1996-06-04 Method of treating malignant tumors with thyroxine analogues having no significant hormonal activity
US08/833,272 US6017958A (en) 1996-06-04 1997-04-03 Method of treating malignant tumors with thyroxine analogues having no significant hormonal activity
PCT/US1997/009086 WO1997046228A1 (en) 1996-06-04 1997-05-30 Method of treating malignant tumors with thyroxine analogues having no significant hormonal activity

Publications (1)

Publication Number Publication Date
IL127384A0 true IL127384A0 (en) 1999-10-28

Family

ID=27096941

Family Applications (1)

Application Number Title Priority Date Filing Date
IL12738497A IL127384A0 (en) 1996-06-04 1997-05-30 Method of treating malignant tumors with thyroxine analogues having no significant hormonal activity

Country Status (15)

Country Link
US (1) US6017958A (xx)
EP (1) EP0954299B1 (xx)
JP (1) JP4188416B2 (xx)
CN (1) CN1154486C (xx)
AT (1) ATE300292T1 (xx)
AU (1) AU730261B2 (xx)
BR (1) BR9710686A (xx)
CA (1) CA2257235C (xx)
DE (1) DE69733834T2 (xx)
DK (1) DK0954299T3 (xx)
ES (1) ES2246514T3 (xx)
IL (1) IL127384A0 (xx)
NZ (1) NZ333356A (xx)
PT (1) PT954299E (xx)
WO (1) WO1997046228A1 (xx)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5922775A (en) * 1997-10-23 1999-07-13 Octamer, Inc. Method of treating malignant tumors with ketone thyroxine analogues having no significant hormonal activity
US6433012B1 (en) * 1998-03-25 2002-08-13 Large Scale Biology Corp. Method for inhibiting inflammatory disease
KR20010042168A (ko) * 1998-03-25 2001-05-25 바이오소스 테크놀로지스 인코포레이티드 혈관형성을 저해하는 벤조에이트 유도체
US6740680B1 (en) * 1999-04-26 2004-05-25 Becton Pharma, Inc. Pharmaceutical compositions to tetrac and methods of use thereof
US6638977B1 (en) 1999-11-19 2003-10-28 Corvas International, Inc. Plasminogen activator inhibitor antagonists
WO2001036351A2 (en) 1999-11-19 2001-05-25 Corvas International, Inc. Plasminogen activator inhibitor antagonists related applications
US7504435B2 (en) 2001-01-31 2009-03-17 The Arizona Board Of Regents On Behalf Of The University Of Arizona Method for stimulating weight loss and/or for lowering triglycerides in patients
US20050159490A1 (en) * 2001-01-31 2005-07-21 Eugene Morkin Method to treat chronic heart failure and/or elevated cholesterol levels
AUPR500201A0 (en) 2001-05-14 2001-06-07 Commonwealth Scientific And Industrial Research Organisation Recovery of minerals by flotation
ATE520653T1 (de) 2002-06-06 2011-09-15 Canbas Co Ltd Verbindungen, die den durch dna-schädigung induzierten g2-checkpoint des zellzyklus stilllegen und/oder die antikrebswirkung von dna- schädigenden behandlungen erhöhen
JP2007501608A (ja) * 2003-08-08 2007-02-01 株式会社 キャンバス 抗癌治療の効力を推定するための感受性試験
US20050249667A1 (en) * 2004-03-24 2005-11-10 Tuszynski Jack A Process for treating a biological organism
CA2615374A1 (en) * 2005-07-18 2007-01-25 Ernest Kun Kun Treatment of cancer
EP1953148B1 (en) 2005-10-28 2012-02-29 Takeda Pharmaceutical Company Limited Heterocyclic amide compound and use thereof
US20100279327A1 (en) * 2006-06-12 2010-11-04 Bipar Sciences, Inc. Method of treating diseases with parp inhibitors
US20080262062A1 (en) * 2006-11-20 2008-10-23 Bipar Sciences, Inc. Method of treating diseases with parp inhibitors
US20070292883A1 (en) * 2006-06-12 2007-12-20 Ossovskaya Valeria S Method of treating diseases with PARP inhibitors
WO2008030887A2 (en) * 2006-09-05 2008-03-13 Bipar Sciences, Inc. Methods for designing parp inhibitors and uses thereof
JP2010502730A (ja) * 2006-09-05 2010-01-28 バイパー サイエンシズ，インコーポレイティド 癌の治療法
AU2007292306A1 (en) * 2006-09-05 2008-03-13 Bipar Sciences, Inc. Inhibition of fatty acid synthesis by PARP inhibitors and methods of treatment thereof
US7538252B2 (en) * 2006-09-05 2009-05-26 Bipar Sciences, Inc. Drug design for tubulin inhibitors, compositions, and methods of treatment thereof
WO2008039941A2 (en) 2006-09-27 2008-04-03 The Government Of The Usa As Represented By The Secretary Of The Dpt. Of Health And Human Services Scgb3a2 as a growth factor and anti-apoptotic agent
WO2009051815A1 (en) * 2007-10-19 2009-04-23 Bipar Sciences, Inc. Methods and compositions for the treatment of cancer using benzopyrone-type parp inhibitors
KR20100102607A (ko) * 2007-11-12 2010-09-24 바이파 사이언스 인코포레이티드 Ｐａｒｐ 억제제를 단독으로 사용하거나 항종양제와 병용하여 자궁암 및 난소암을 치료하는 방법
CN103169973A (zh) * 2007-11-12 2013-06-26 彼帕科学公司 使用4-碘-3-硝基苯甲酰胺化合物与抗肿瘤剂组合治疗乳腺癌
CN101888777A (zh) * 2007-12-07 2010-11-17 彼帕科学公司 用拓扑异构酶抑制剂和parp抑制剂的组合治疗癌症
WO2009100159A2 (en) * 2008-02-04 2009-08-13 Bipar Sciences, Inc. Methods of diagnosing and treating parp-mediated diseases
WO2011135574A1 (en) 2010-04-28 2011-11-03 Osnat Ashur-Fabian Methods, compositions and kits for providing a therapeutic treatment
MX353618B (es) * 2012-08-20 2018-01-22 Merck Patent Gmbh Preparación farmacéutica sólida que contiene levotiroxina.
US10874641B2 (en) 2016-07-28 2020-12-29 Mitobridge, Inc. Methods of treating acute kidney injury
CN110300600A (zh) 2016-11-02 2019-10-01 伊缪诺金公司 利用抗体-药物缀合物和parp抑制剂的组合治疗
US11433074B2 (en) 2017-06-22 2022-09-06 Triact Therapeutics, Inc. Methods of treating glioblastoma
EP3687501A4 (en) 2017-09-29 2021-06-23 Triact Therapeutics, Inc. INIPARIB FORMS AND USES THEREOF
US11874276B2 (en) 2018-04-05 2024-01-16 Dana-Farber Cancer Institute, Inc. STING levels as a biomarker for cancer immunotherapy
WO2021041532A1 (en) 2019-08-26 2021-03-04 Dana-Farber Cancer Institute, Inc. Use of heparin to promote type 1 interferon signaling

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB643089A (en) * 1947-10-23 1950-09-15 Glaxo Lab Ltd Improvements in or relating to the preparation of 2:6-dihalogeno diphenyl ethers
GB642159A (en) * 1947-10-23 1950-08-30 Glaxo Lab Ltd Improvements in or relating to the preparation of diphenyl ethers
US4724234A (en) * 1982-09-17 1988-02-09 Therapeutical Systems Corp. Method for producing oncolysis
US4816255A (en) * 1985-07-31 1989-03-28 Ghent William R Treatment of iodine deficiency breast syndrome
WO1993002444A1 (en) * 1991-07-24 1993-02-04 Vladislav Vladimirovich Volkov Tensioning device for keyboard stringed musical instrument
WO1993024442A1 (en) * 1992-05-29 1993-12-09 Yamanouchi Pharmaceutical Co., Ltd. Medicine containing benzoic acid derivative and novel benzoic acid derivative
US5736576A (en) * 1996-06-04 1998-04-07 Octamer, Inc. Method of treating malignant tumors with thyroxine analogues having no significant hormonal activity
US5883294A (en) * 1997-06-18 1999-03-16 The Regeants Of The University Of California Selective thyroid hormone analogs
US5922775A (en) * 1997-10-23 1999-07-13 Octamer, Inc. Method of treating malignant tumors with ketone thyroxine analogues having no significant hormonal activity

Also Published As

Publication number Publication date
CA2257235A1 (en) 1997-12-11
AU730261B2 (en) 2001-03-01
JP4188416B2 (ja) 2008-11-26
DE69733834D1 (de) 2005-09-01
PT954299E (pt) 2005-11-30
ATE300292T1 (de) 2005-08-15
WO1997046228A1 (en) 1997-12-11
BR9710686A (pt) 2000-01-11
CA2257235C (en) 2007-01-30
US6017958A (en) 2000-01-25
DK0954299T3 (da) 2005-10-31
AU3218297A (en) 1998-01-05
NZ333356A (en) 2000-06-23
DE69733834T2 (de) 2006-06-01
EP0954299A1 (en) 1999-11-10
EP0954299A4 (en) 2000-09-06
JP2001501590A (ja) 2001-02-06
CN1154486C (zh) 2004-06-23
ES2246514T3 (es) 2006-02-16
CN1226826A (zh) 1999-08-25
EP0954299B1 (en) 2005-07-27

Similar Documents

Publication Publication Date Title
IL127384A0 (en) Method of treating malignant tumors with thyroxine analogues having no significant hormonal activity
AU1195499A (en) Thyroxine analogues having no significant hormonal activity to treat malignant tumors
DE69830072D1 (de) Radioaktive zusammensetzungen zur behandlung von prostatatumoren
CA2276606A1 (en) Method of treating prostatic diseases using active vitamin d analogues
PL323798A1 (en) Application of derivatives of vitamin d4 in treating skin diseases
CA2301032A1 (en) A method of preventing or treating estrogen-dependent diseases and disorders
AU7585498A (en) Inhibition of p38 kinase activity by aryl ureas
MX9804009A (es) Inhibicion de crecimiento tumoral por oligonucleotidos de antisentido para il-8 y receptor de il-8.
NO960445D0 (no) Hudplaster og fremgangsmåter for å administrere testosteron
UA39158C2 (uk) Похідні n4-оксикарбоніл-5'-дезокси-5-фторцитидину та фармацевтичний препарат на їх основі
ATE222769T1 (de) Verabreichung von gm-csf zur behandlung der gehirntumoren und verhütung deren wiederauftretens
ATE249233T1 (de) Verwendung von gonadotropin releasing hormon analogen oder änlichen verbindungen zur herstellung von pharmazeutischen zubereitungen als zusatz für invasiver behandlung von karzinomen
AU6178198A (en) Method of treating a tumor
PA8453601A1 (es) Inhibidores de la farnesil transferasa combinados con inhibidores de la hmg coa reductasa para tratamiento del cancer
PT100111A (pt) Composicao para o tratamento de um mamifero sofrendo de doenca proliferativa dapele, benigna ou maligna, compreendendo um analogo de somatostatina
DE69732851D1 (de) Verwendung von dextrinsulfat zur behandlung von sehr vasculären tumoren
MX9606137A (es) Composiciones y metodos para el tratamiento de tumores.
MX9700398A (es) Solucion para la modificacion de tumores cancerosos.
ECSP982800A (es) Metodos para el tratamiento de enfermedades proliferativas
MX9701832A (es) Nuevos profarmacos para la terapia de tumores y enfermedades inflamatorias.